Vesicular drug delivery systems: Promising approaches in ocular drug delivery

Yükleniyor...
Küçük Resim

Tarih

2024

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

MDPI

Erişim Hakkı

info:eu-repo/semantics/openAccess

Araştırma projeleri

Organizasyon Birimleri

Dergi sayısı

Özet

Ocular drug delivery poses unique challenges due to the complex anatomical and physiological barriers of the eye. Conventional dosage forms often fail to achieve optimal therapeutic outcomes due to poor bioavailability, short retention time, and off-target effects. In recent years, vesicular drug delivery systems have emerged as promising solutions to address these challenges. Vesicular systems, such as liposome, niosome, ethosome, transfersome, and others (bilosome, transethosome, cubosome, proniosome, chitosome, terpesome, phytosome, discome, and spanlastics), offer several advantages for ocular drug delivery. These include improved drug bioavailability, prolonged retention time on the ocular surface, reduced systemic side effects, and protection of drugs from enzymatic degradation and dilution by tears. Moreover, vesicular formulations can be engineered for targeted delivery to specific ocular tissues or cells, enhancing therapeutic efficacy while minimizing off-target effects. They also enable the encapsulation of a wide range of drug molecules, including hydrophilic, hydrophobic, and macromolecular drugs, and the possibility of combination therapy by facilitating the co-delivery of multiple drugs. This review examines vesicular drug delivery systems, their advantages over conventional drug delivery systems, production techniques, and their applications in management of ocular diseases.

Açıklama

Anahtar Kelimeler

Ocular Drug Delivery, Vesicular Systems, Liposomes, Targeted Delivery, Sustained Release

Kaynak

Pharmaceuticals

WoS Q Değeri

Q2

Scopus Q Değeri

Q2

Cilt

17

Sayı

4

Künye

Batur, E., Özdemir, S., Durgun, M. E., & Özsoy, Y. (2024). Vesicular drug delivery systems: Promising approaches in ocular drug delivery. Pharmaceuticals, 17(4), 1-27. https://doi.org/10.3390/ph17040511